Biocon receives EIR from USFDA for aseptic drug product facility

20 Nov 2017 Evaluate

Biocon has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between May 25, 2017 to June 3, 2017. The USFDA has classified the outcome of this inspection as VAI (voluntary action indicated) and the EIR states that the inspection is closed.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×